The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Orosur Mining drops on disappointing assays

Fri, 02nd Dec 2022 10:40

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Premier Miton Group PLC, up 14% at 104.00 pence, 12-month range 84.69p - 207.00p. Reports both profit and assets under management declined in the year ended September 30. The asset manager posts pretax profit of GBP14.9 million, down 15% from GBP17.5 million a year earlier. Assets under management at September 30 were GBP10.57 billion, down 24% from GBP13.93 billion. More positively, assets under management recover to around GBP11.3 billion at November 25 and the firm sees a return to net positive flows in its funds during the first two months of its current financial year. Chief Executive Mark O'Shea says the results are "resilient" despite tougher market conditions and adds the firm is "well-positioned" to achieve its long-term growth ambitions.

----------

Tern PLC, up 5.0% at 11.03 pence, 12-month range 6.60p - 18.89p. Notes that Device Authority Ltd has expanded its business and technology relationship with an existing "tier one" automotive supply chain customer, winning a contract value of over USD1.2 million over five years. Tern has a 54% stake in the internet of things technology firm. The contract is for the deployment of Device Authority's KeyScaler technology which provides identity management services.

----------

AIM - LOSERS

----------

Orosur Mining Inc, down 31% at 8.78 pence, 12-month range 7.03p - 19.00p. Reports disappointing assay results for four additional diamond holes at the Pepas and Pupino prospects at its Anza project in Colombia. The project is a joint venture with Colombian company Minera Monte Aguila. The assay results indicate the best grade of gold and silver was found at Pepas hole number 009. The results at Pepas 009 show lower levels of gold mineralisation than intersected in previous drilling. No significant results were found at the Pupino prospect. The firm adds it will now shift its focus to groundwork.

----------

ReNeuron Group PLC, down 18% at 18.35 pence, 12-month range 15.00p - 95.22p. Says that it has been investigating an equity raise with investors, but explains "unfavourable conditions" in small-cap equity markets meant this was not possible. Adds that, following a review of its cost base and planned initiatives, savings have been identified in order to extend the firm's cash runway until "at least the start of the fourth calendar quarter of 2023" to ensure the continued development of its technology platform. The stem cell and exosomes technology company also reports a narrowed loss in in the six months ended September 30. Pretax loss totals GBP3.8 million, narrowed from a loss of GBP6.0 million the year before. ReNeuron's revenue multiplies to GBP438,000 from GBP58,000 the year before.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2014 05:24

UK AGM, EGM Calendar - Week Ahead

Read more
28 Aug 2014 15:11

UK AGM, EGM Calendar - Week Ahead

Read more
28 Aug 2014 05:31

UK AGM, EGM Calendar - Week Ahead

Read more
27 Aug 2014 15:25

UK AGM, EGM Calendar - Week Ahead

Read more
27 Aug 2014 05:53

UK AGM, EGM Calendar - Week Ahead

Read more
26 Aug 2014 15:16

UK AGM, EGM Calendar - Week Ahead

Read more
25 Jul 2014 09:40

DIRECTOR DEALINGS: ReNeuron Group Directors Buy Shares

Read more
23 Jul 2014 14:17

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

Read more
18 Jun 2014 13:29

ReNeuron well set after 'transformational' year

Stem cell treatment developer ReNeuron lost an increased £7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year. The AIM-listed compa

Read more
18 Jun 2014 11:47

UK MIDDAY BRIEFING: BOE Policy Makers Still Unanimous

LONDON (Alliance News) - Bank of England policymakers unanimously decided to leave the key interest rates and asset purchase programme unchanged at the monetary policy meeting held on June 4 and 5, the minutes of the meeting showed Wednesday.

All nine members of the Monetary Policy

Read more
18 Jun 2014 08:27

ReNeuron Confident For Future Despite Loss As It Advances Therapies

LONDON (Alliance News) - ReNeuron Group PLC Wednesday expressed confidence in its future as it continued to develop its stem-cell therapies towards commercialisation, and it posted a widened loss in the year to end-March. The company posted a pretax loss of GBP7.8 million, widened from GBP7

Read more
18 Jun 2014 07:21

UK MORNING BRIEFING: Zoopla Prices IPO As Markets Await Central Banks

LONDON (Alliance News) - UK shares have opened higher Wednesday, following a firm close on Wall Street and ahead of central bank announcements in the UK and US.

There was further IPO activity Wednesday, as property website Zoopla Property Group said it will price it

Read more
7 May 2014 14:15

ReNeuron Says Stroke Disability Therapy Study Yielding "Encouraging" Results

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC Wednesday said that its PISCES study of its ReN001 stem cell therapy for stroke disability has continued to yield encouraging results. The company said that there was no cell-related or immunological adverse events report

Read more
23 Apr 2014 12:02

ReNeuron seeks to expand board with new CEO

A new chief executive is being sought by AIM-listed stem cell specialist ReNeuron as it enters the next stage of its development. Current Chief Executive Michael Hunt will remain in the role until a replacement is recruited, when he will become Chief Financial Officer. Chairman Bryan Morton said:

Read more
23 Apr 2014 11:37

ReNeuron Seeking New Chief Executive, Current To Become Financial Officer

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday that it was appointing a new Chief Executive Officer to replace Michael Hunt, who will be moving into the role of Chief Financial Officer when a successor has been recruited. The company said that, as a result of the progress it has

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.